Accessibility Menu
Curative Biotechnology logo

Curative Biotechnology(OTC) CUBT

Market Cap$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-96%
1 Year-33%
1 Month-40%
$0.75
-16.67%
-0.15Today
Curative Biotechnology last closing stock price
MetricPriceDate
Last closeUSD 0.752026-09-04
Curative Biotechnology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.67%USD 0.902026-08-28
1 month-40%USD 1.252026-08-05
3 month-52.53%USD 1.582026-06-05
Year to date-7.41%USD 0.812025-12-31
1 year-33.11%USD 1.122025-09-04
3 year-64.29%USD 2.102023-09-05
5 year-95.8%USD 17.852021-09-03
Since inception-99.99%USD 7,499.962008-02-22

Curative Biotechnology Financials at a Glance

Market Cap

$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.03M

EPS (TTM)

-$0.40

P/E Ratio

-1.86

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.75

Volume

100

Open

$0.75

Previous Close

$0.75

Daily Range

$0.75 - $0.75

52-Week Range

$0.03 - $1.99

Estimated Earnings Date

Aug 14, 2026

CUBT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Curative Biotechnology

Curative Biotechnology, Inc. is an emerging biomedical firm focused on developing innovative pharmaceutical products. The company targets critical therapeutic areas, including infectious diseases, cancer, and degenerative eye conditions, with a diverse pipeline of promising candidates.

Products and Services
  • IMT504: An immunotherapy for rabies treatment and vaccine enhancement
  • CUBT906: A monoclonal antibody targeting tumor cells for cancer treatment
  • Reformulated Metformin: Aimed at managing degenerative eye disorders
Growth Outlook
  • Partnership with Mid-Atlantic BioTherapeutics to advance IMT504
  • Focus on high-demand therapeutic areas with significant market potential
  • Continued investment in R&D to expand product pipeline
Financial Highlights
  • Recent quarterly net income of -$370,269, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating early-stage development
  • Cash and cash equivalents of $44,801 as of March 31, 2026
Curative Biotechnology, Inc. is positioned in the biotechnology sector, with a focus on addressing unmet medical needs through innovative therapies. The company has made strides in its research and development efforts, particularly with its key pipeline assets. The partnership with Mid-Atlantic BioTherapeutics is a strategic move to enhance the development of IMT504, which could significantly impact the treatment landscape for rabies and COVID-19. Despite the current financial challenges, including a net income loss and no revenue, the emphasis on R&D and the potential for future product launches may attract investor interest. The company's commitment to advancing its pipeline and exploring new therapeutic areas underscores its long-term growth potential in the biotechnology industry.
AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3

CEO

I. Richard Garr

Website

www.curativebiotech.com

Headquarters

Palm Beach Gardens, FL 33410, US

CUBT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

33.00%

Return on Capital

N/A

Return on Assets

-94.24%

Earnings Yield

-53.76%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.82M

Volume

100

Avg. Volume

817.141

Financials (TTM)

Gross Profit

-$87.10K

Operating Income

-$1.23M

EBITDA

-$1.14M

Operating Cash Flow

-$1.03M

Capital Expenditure

$5.00

Free Cash Flow

-$1.03M

Cash & ST Invst.

$145.26K

Total Debt

$1.36M

Curative Biotechnology Performance Analysis

Curative Biotechnology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Curative Biotechnology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Curative Biotechnology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.43-74.5%
20232023-12-31USD -1.32-8.1%
20242024-12-31USD -0.58-55.9%
20252025-12-31USD -0.44-23.7%
Curative Biotechnology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-9.1%
Q42025-12-3166.2%
Q12026-03-31-109.6%
Q22026-06-30-88.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$21.78K

+2.6%

Gross Margin

0.00%

N/A

Market Cap

$5.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.28M

N/A

Employees

4

N/A

Net Income

-$608.91K

+14.3%

EBITDA

-$351.24K

+45.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$145.26K

+439.9%

Total Debt

$1.36M

-2.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.36M

-2.5%

Return on Assets

-94.24%

N/A

Return on Invested Capital

19.27%

N/A

Free Cash Flow

-$341.83K

-79.6%

Operating Cash Flow

-$341.83K

-79.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TXTMProText Mobility, Inc.
$0.00-1.41%
BVAXFBioVaxys Technology Corp.
$0.07+0.00%
FAMDFFutura Medical plc
$0.00+4.00%
THERTheralink Technologies, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CUBT

What is the current price of Curative Biotechnology?

Curative Biotechnology is trading at $0.75 per share.

What is the 52-week range for Curative Biotechnology?

Over the past 52 weeks, Curative Biotechnology has traded between $0.03 and $1.99.

How much debt does Curative Biotechnology have?

As of the most recent reporting period, Curative Biotechnology reported total debt of $1.36M.

How much cash does Curative Biotechnology have on hand?

Curative Biotechnology reported $145.26K in cash and cash equivalents in its most recent financial results.

What is Curative Biotechnology’s dividend yield?

Curative Biotechnology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services